1187055-40-8

Basic information

• Product Name: benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate
• Synonyms: benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate
• CAS NO: 1187055-40-8
• Molecular Weight: 348.399
• Mol File: 1187055-40-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate(1187055-40-8)
• EPA Substance Registry System: benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate(1187055-40-8)

Safety Data

• Hazardous Substances Data: 1187055-40-8(Hazardous Substances Data)

Upstream product

• 51-35-4 4R-4-hydroxyproline 
• 1187055-35-1 benzyl (3S,5R)-3-(tert-butoxycarbonylamino)-5-[tert-butyl(dimethyl)silyl]oxy-piperidine-1-carboxylate 
• 849161-65-5 tert-butyl N-[(3S,5R)-5-[tert-butyl(dimethyl)silyl]oxy-3-piperidyl]carbamate 
• 708253-91-2 tert-butyl N-[(3S,5R)-1-benzyl-5-[tert-butyl(dimethyl)silyl]oxy-3-piperidyl]carbamate 
• 708253-90-1 [(3R,5S)-5-azido-1-benzyl-3-piperidyl]oxy-tert-butyl-dimethylsilane 
• 635299-81-9 [(2R,4R)-1-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-pyrrolidin-2-yl]methanol 
• 1271809-99-4 methyl (2R,4R)-1-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-pyrrolidine-2-carboxylate 
• 114676-53-8 (2R,4R)-methyl 1-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 114676-47-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 2584-71-6 cis-hydroxy-D-proline 
• 1187055-36-2 benzyl (3S,5R)-3-(tert-butoxycarbonylamino)-5-hydroxypiperidine-1-carboxylate 

Downstream Products

• 1187055-44-2 (S)-benzyl 3-(tert-butoxycarbonylamino)-5-ethylidenepiperidine-1-carboxylate 
• 1187055-41-9 benzyl (5S)-5-(tert-butoxycarbonylamino)-3,3-difluoropiperidine-1-carboxylate 
• 1562988-38-8 (S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

PIM KINASE INHIBITORS AND METHODS OF THEIR USE

The present invention relates to new compounds of Formulas (I) and (II), their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmac